Lili Z Wang

US Patent:

20180148408, May 31, 2018

Filed:

Sep 28, 2017

Appl. No.:

15/718987

Inventors:

- New Brunswick NJ, US
- Cambridge MA, US
Lin Chen - Piscataway NJ, US
Timothy Lewis - Marlborough MA, US
Ben Munoz - Netwonville MA, US
Lili Wang - Chestnut Hill MA, US

International Classification:

C07D 209/48
A61K 31/472
C07D 207/452
C07D 405/12
C07D 401/06
A61K 31/4725
C07D 401/14
G01N 33/50
C07D 217/16
C07D 335/06

Abstract:

A method of identifying compounds as direct inhibitors of Keap1-Nrf2 interaction through high-throughput screening and lead development. The direct inhibitors of Keap1-Nrf2 interaction are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential drug candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, and Parkinson's. Novel compounds are identified and methods of preventing or treating diseases or conditions related to Keap1-Nrf2 interaction activity by use of the novel compounds identified or compositions containing such compounds are also disclosed.

US Patent:

20140256767, Sep 11, 2014

Filed:

Oct 31, 2012

Appl. No.:

14/355419

Inventors:

- New Brunswick NJ, US
- Cambridge MA, US
Lin Chen - Piscataway NJ, US
Timothy Lewis - Marlborough MA, US
Ben Munoz - Netwonville MA, US
Lili Wang - Chestnut Hill MA, US

Assignee:

THE BROAD INSTITUTE, INC. - Cambridge MA
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY - New Brunswick NJ

International Classification:

C07D 401/14
G01N 33/50
C07D 209/48
C07D 401/06
C07D 217/16

US Classification:

514296, 514307, 546146, 546 99, 514323, 546201, 514417, 548473, 506 10

Abstract:

A method of identifying compounds as direct inhibitors of Keap1-Nrf2 interaction through high-throughput screening and lead development. The direct inhibitors of Keap1-Nrf2 interaction are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential drug candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, and Parkinson's. Novel compounds are identified and methods of preventing or treating diseases or conditions related to Keap1-Nrf2 interaction activity by use of the novel compounds identified or compositions containing such compounds are also disclosed.